Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Francisco, CA
NPI
1891746129
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
5
Hospital affiliations
1580 Valencia St, Ste 102
San Francisco, CA, 94110
Phone (415) 695-7661
Medicare paid, 2024
$396K
5,831 services
Medicare patients, 2024
450
Average age 75
Drug cost, 2024
$7.3M
13,019 prescriptions
Company payments, 2025
$59K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Cheng-Yang C Tuan was code 99489 (chronic, principal, and transitional care management), 1,251 times for 119 patients. In total Cheng-Yang C Tuan billed 5,831 services in 20 codes, and Medicare paid $396K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99489 Chronic, Principal, and Transitional Care Management | Office | 1,251 | 119 | $68.43 | $86K |
| 99458 E&M - Miscellaneous | Office | 1,218 | 117 | $36.80 | $45K |
| 99214 Office E&M - Established | Office | 817 | 359 | $112.41 | $92K |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 725 | 120 | $126.56 | $92K |
| 99457 E&M - Miscellaneous | Office | 691 | 117 | $46.85 | $32K |
| 99454 E&M - Miscellaneous | Office | 302 | 107 | $51.59 | $16K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 219 | 162 | $14.52 | $3,180 |
| 95251 Test - Miscellaneous | Office | 217 | 93 | $30.57 | $6,634 |
| 99213 Office E&M - Established | Office | 148 | 122 | $66.67 | $9,868 |
| 99453 E&M - Miscellaneous | Office | 86 | 84 | $20.61 | $1,772 |
| 99442 Telephone Services | Office | 39 | 33 | $62.87 | $2,452 |
| 99497 Care Management/Coordination | Office | 23 | 23 | $71.42 | $1,643 |
| 95250 Test - Miscellaneous | Office | 23 | 20 | $162.45 | $3,736 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 14 | 12 | $53.01 | $742 |
By year: 2022 $190K for 1,926 services; 2023 $162K for 1,658 services; 2024 $396K for 5,831 services.
Medicare prescription drug claims, 2024
In 2024, the drug Cheng-Yang C Tuan prescribed most often to Medicare patients was Jardiance (Empagliflozin), with 1,216 prescriptions and refills. In total Cheng-Yang C Tuan wrote 13,019 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | 1,216 | 2,576 | 288 | $1.5M |
| Ozempic Semaglutide | 1,180 | 2,067 | 260 | $2.0M |
| Metformin Hcl Er Metformin Hcl | 950 | 2,639 | 286 | $20K |
| Levothyroxine Sodium Generic | 843 | 2,323 | 210 | $11K |
| Atorvastatin Calcium Generic | 761 | 2,120 | 232 | $10K |
| Metformin Hcl Generic | 485 | 1,420 | 145 | $7,226 |
| Pioglitazone Hcl Generic | 405 | 1,196 | 118 | $7,233 |
| Farxiga Dapagliflozin Propanediol | 389 | 765 | 87 | $409K |
| Amlodipine Besylate Generic | 349 | 1,006 | 108 | $2,609 |
| Losartan Potassium Generic | 342 | 953 | 101 | $4,263 |
| Mounjaro Tirzepatide | 335 | 420 | 60 | $436K |
| Januvia Sitagliptin Phosphate | 307 | 695 | 94 | $363K |
| Trulicity Dulaglutide | 286 | 509 | 64 | $489K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 262 | 735 | 124 | $32K |
| Kerendia Finerenone | 245 | 465 | 53 | $296K |
Brand drugs: 6,519 claims; generic drugs: 5,947 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Cheng-Yang C Tuan $59K ($59K in general payments such as food, travel and fees) from 24 companies. The largest payer was Lilly USA, LLC with $31K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 61 | $31K |
| Novo Nordisk Inc NVO | 39 | $18K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $7,174 |
| Dexcom, Inc. DXCM | 14 | $659 |
| Amgen Inc. AMGN | 18 | $454 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $230 |
| Madrigal Pharmaceuticals MDGL | 7 | $208 |
| Radius Health, Inc. | 6 | $160 |
| Antares Pharma, Inc. | 8 | $150 |
| Abbott Laboratories ABT | 6 | $141 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.